Rayno Biopharmaceutical Portfolio Poised for Big Wins in 2017

Biotech stocks have stalled since hitting highs in early October with pronounced weakness (see Risks Rising) over the past two weeks. Some large caps took a big hit from disappointing earnings (AMGN, GILD) so this points out the need for a balanced diversified portfolio including ETFs. Today was another lackluster day in a mixed market but with major indices holding the 5-day level.

Our biopharmaceutical portfolio is designed for the longer term but we delete stock picks that no longer meets our criteria.

The Rayno Biopharmaceutical Portfolio has done very well in 2017 and here is a brief performance summary:

                  Company Ticker Date Price Price Perf 11/6 Perf %       Started   4/25 % P YTD   Abbvie ABBV 2/3/16 56.5 65.45 16 93 41.48   Amgen AMGN 9/12/16 172 165 -4 170.8 16.8   Biogen BIIB 2/13/17 275 286.5 4.5 315.47 11.25   bluebird bio BLUE 2/3/16 43.75 88.1 103 144.75 134.6   Bristol Myers BMY 2/16/16 61 54.2 -7.7 61.68 5.54   Foundation Med FMI 7/5/16 20.4 34 68 54.35 207   Gilead Sciences GILD 2/3/16 85.8 67.3 -20.9 72.38 1   Roche ADR RHHBY 4/4/16 30.36 32.4 7.9 29.22 2.4                     IBB   6/29/16 250 296 18.4 315.6 18.9   XBI   1/31/17 64 70.7 9.4 85 43.66   QQQ (reference)   n/a   135.13 n/a 153.79 29.8                               220 27.25